Qianhai Health Holdings Limited to Hold Board Meeting for Interim Results and Dividend Consideration
Key Points for Investors:
- Board Meeting Date: The Board of Directors of Qianhai Health Holdings Limited (Stock Code: 911) will hold a meeting on Wednesday, 12 August 2026.
- Purpose of the Meeting:
- To consider and approve the unaudited interim results for the six months ended 30 June 2026.
- To consider publication of the interim financial results.
- To consider and recommend the payment of an interim dividend (if any) to shareholders.
- Board Composition: The Board consists of non-executive, executive, and independent non-executive Directors, notably:
- Chairman: Mr. Huang Zhiqun
- Non-executive Directors: Mr. Huang Zhiqun, Mr. Chen Kaiben, and Mr. Chen Qi
- Executive Directors: Mr. Tang Yu Yuan and Mr. Yuen Chee Lap Carl
- Independent Non-executive Directors: Mr. Li Wei, Mr. Leung Chun Tung, and Ms. Wu Hung Yu
Potentially Price-Sensitive Information for Shareholders:
- The announcement of the Board meeting to consider the interim results and a potential interim dividend could be price-sensitive. Shareholders should closely monitor the outcome, as the release of financial results and any dividend declaration may significantly impact the company’s share price.
- If an interim dividend is recommended and approved, this could provide direct value to shareholders and potentially boost investor sentiment.
- The market typically reacts to interim results, especially if they surpass or fall short of expectations.
Details for Investors:
- The official announcement was made on 29 July 2026 in Hong Kong by Chairman Mr. Huang Zhiqun.
- The Board will discuss and approve the unaudited results, which will offer investors insights into the company’s financial health and performance for the first half of 2026.
- Investors should stay tuned for the official publication of the interim results and any associated dividend announcement after the Board meeting.
What Investors Should Do:
- Review the interim results and dividend proposal (if any) once published, as these are likely to affect the company’s valuation and your investment decisions.
- Monitor official company communications for further updates following the 12 August 2026 Board meeting.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should exercise their own judgment and consult professional advisors before making any investment decisions.
前海健康控股有限公司宣布董事會會議審議中期業績及派息計劃
投資者重點：
- 董事會會議日期： 前海健康控股有限公司（股份代號：911）董事會將於2026年8月12日（星期三）召開會議。
- 會議目的：
- 審議及批准截至2026年6月30日止六個月的未經審核中期業績。
- 考慮公布中期財務業績。
- 考慮及建議派發中期股息（如有）予股東。
- 董事會組成： 董事會包括非執行董事、執行董事及獨立非執行董事，主要成員如下：
- 主席：黃志群先生
- 非執行董事：黃志群先生、陳開本先生、陳琦先生
- 執行董事：唐裕源先生、阮志立先生
- 獨立非執行董事：李偉先生、梁振東先生、吳虹瑜女士
可能影響股價的重要事項：
- 公布董事會會議以審議中期業績及潛在派息屬於或有價格敏感信息。股東應密切留意會議結果，因為財務業績及股息宣布有可能顯著影響公司股價。
- 如建議並通過派發中期股息，這將直接為股東帶來價值，並有望提升市場信心。
- 市場通常對中期業績有明顯反應，尤其是業績超預期或不如預期時。
投資者需知詳情：
- 本公告於2026年7月29日由董事會主席黃志群先生於香港發布。
- 董事會將審議及批准未經審核業績，這將為投資者提供2026年上半年公司財務狀況及表現的重要信息。
- 投資者應留意董事會會議後公司正式公布的中期業績及任何派息公告。
投資者行動建議：
- 在公布中期業績及股息建議（如有）後，投資者應審慎評估，因為這些訊息可能會影響公司估值及您的投資決策。
- 密切關注2026年8月12日董事會會議後公司的官方公告。
免責聲明：本文僅供參考，不構成投資建議。投資者應根據自身判斷並諮詢專業顧問作出投資決策。
